Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.42) by 3...
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was hi...
Morgan Stanley analyst Jeffrey Hung initiates coverage on CervoMed (NASDAQ:CRVO) with a Overweight rating and announces Pric...
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $65 price target.
Brookline Capital analyst Tyler Bussian initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price T...
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, to...
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value ind...
Jones Trading analyst Soumit Roy initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target o...
